Supplementary Tables S1-S5 Supplementary Fig. 2 Further structural interrogation of human lung N-glycans. (a) MALDI-TOF/TOF-MS/MS analysis of a permethylated human lung N-glycan at m/z 3212 confirmed the expression of a bisecting GlcNAc. The fragment ion at m/z 1563 was generated from double-cleavage fragmentation, which indicated a GlcNAc residue was attached to the tri-mannosyl core. The loss of a terminal GlcNAc was confirmed by the detection of Y-ion at m/z 2953. (b) MALDI-TOF/TOF-MS/MS analysis of a permethylated human lung N-glycan at m/z 3852 confirmed the expression of Lewis antigens. The B-ion at m/z 660 represented a fucosylated LacNAc trisaccharide fragment ion, which indicated the expression of an H antigen or a terminal LeX antigen. The expression of SLeX was also detected which was confirmed by the B-ion at m/z 1021 together with its corresponding Y-ion at 2852. Detection of a double cleavage ion at m/z 646 suggested the presence of internal LeX motif as well as SLeX. (c) MALDI-TOF/TOF-MS/MS analysis of a permethylated human lung N-glycan at m/z 4138 confirmed the Neu5Ac-GlcNAc sequence. The addition of a fourth sialic acid on the GlcNAc of a LacNAc unit was confirmed by the presence of the fragment ion at m/z 611. The MS/MS spectra of all three molecular ions confirmed core-fucosylation as illustrated by the fragment ion at m/z 474. (d) The doughnut charts represented the relative quantitation of human lung complex N-glycans with sialylation, fucosylation or bisection. The percentage was defined as the sum of relative intensities carrying that specific structural feature divide by the sum of relative intensities of total glycans. Glycans with more than one sialic acid or fucose residue were further dissected to reflect the proportions carrying various numbers of sialic acid or fucose residues. Bisected glycans were further inspected to show the proportions of sialylated and fucosylated species. Supplementary Fig. 3 N- glycan MS profiles of human lung following neuraminidase treatment. The spectra cover the m/z region between 7000 and 12000. All molecular ions detected represent permethylated species and are present in the form of [M+Na]+. (a) MALDI-TOF-MS spectrum of untreated human lung N-glycans. (b) MALDI-TOF-MS spectrum of human lung N-glycans treated with neuraminidase A. (c) MALDI-TOF-MS spectrum of human lung N-glycans treated with neuraminidase S. Peaks representing sialylated glycans are colored in red, non-sialylated glycans are in black and bisected glycans are underlined.
Western blot of human lung for detection of Lewis glycan epitopes. Tissue homogenate in human lung were treated with PNGase F (PNGaseF), Neuraminidase A (NeuA), or Neuraminidase S (NeuS), and separated by SDS-PAGE. The gel was analyzed by Western blot using antibodies against LeA (a), SLeA (b) and LeX (c) . HRP-conjugated goat anti-mouse IgM (d), goat antimouse IgG (e), and Streptavidin (f) were used as quality control. Fig. 7 Western blot of human lung-2. Tissue homogenate obtained from human lung-2 were treated with PNGase F (PNGaseF), Neuraminidase A (NeuA), or Neuraminidase S (NeuS) and separated by SDS-PAGE. The gel was stained with Coomassie Brilliant Blue solution (a). Western blot was performed on the second human lung homogenate using lectins ConA (b), SNA (c), MAL-I (d), AAL (e), UEA-I (f), DBA (g) as well as antibodies against LeA (h), SLeA (i) and LeX (j). HRP-conjugated goat anti-mouse IgM (k), goat anti-mouse IgG (l), Streptavidin (m) and β-actin antibody (n) were used as quality control. Fig. 9 Immunofluorescence staining of human lung sections. The localization of Lewis antigens were visualized by immunofluorescence staining of human lung sections. Tissue sections were counterstained with a nucleus marker DAPI and an epithelium marker EpCAM. 
